₹1,056 crore. The company also posted a 32% rise in its third-quarter profit, beating analysts estimates.
Generic drugmaker's total revenue from operations for Q3 FY24 saw a marginal dip at ₹6,603 crore as compared to ₹6,678 crore in the previous quarter. (More to come)Milestone Alert!
Livemint tops charts as the fastest growing news website in the world